Orally administered amyloidophilic compound is effective in prolonging the incubation periods of animals cerebrally infected with prion diseases in a prion strain-dependent manner

Journal of Virology

Volumn 81, Issue 23, 2007, Pages 12889-12898

  Kawasaki, Yuri ^a   Kawagoe, Keiichi ^b   Chen, Chun Jen ^b   Teruya, Kenta ^a   Sakasegawa, Yuji ^a   Doh Ura, Katsumi ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROPROTECTIVE AGENT; PRION PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; INCUBATION TIME; INOCULATION; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PRION DISEASE; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; SYRIAN HAMSTER;

ADMINISTRATION, ORAL; ANIMALS; BRAIN; BRAIN CHEMISTRY; CELL LINE; FLOW CYTOMETRY; HETEROCYCLIC COMPOUNDS; IMMUNOBLOTTING; MICE; PRION DISEASES; PRIONS;

ANIMALIA; MUS;

EID: 36348929457     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01563-07     Document Type: Article

References (32)

1. Adjou, K. T., J. P. Deslys, R. Demaimay, and D. Dormont. 1997. Probing the dynamics of prion diseases with amphotericin B. Trends Microbiol. 5:27-31.
2. Bresjanac, M., L. M. Smid, T. D. Vovko, A. Petric, J. R. Barrio, and M. Popovic. 2003. Molecular-imaging probe 2-(1-[6-[(2-fluoroethyl)(methyl)- amino]-2-naphthyl]ethylidene)malononitrile labels prion plaques in vitro. J. Neurosci. 23:8029-8033.
3. Cai, L., R. B. Innis, and V. W. Pike. 2007. Radioligand development for PET imaging of beta-amyloid (Abeta) - current status. Curr. Med. Chem. 14:19-52.
4. Cashman, N. R., and B. Caughey. 2004. Prion diseases - close to effective therapy? Nat. Rev. Drug Discov. 3:874-884.
5. Caughey, B., and R. E. Race. 1992. Potent inhibition of scrapie-associated PrP accumulation by Congo red. J. Neurochem. 59:768-771.
6. Caughey, B., and G. J. Raymond. 1993. Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J. Virol. 67:643-650.
7. Doh-ura, K., E. Mekada, K. Ogomori, and T. Iwaki. 2000. Enhanced CD9 expression in the mouse and human brains infected with transmissible spongiform encephalopathies. J. Neuropathol. Exp. Neurol. 59:774-785.
8. Doh-Ura, K., T. Iwaki, and B. Caughey. 2000. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J. Virol. 74:4894-4897.
9. Doh-ura, K., K. Ishikawa, I. Murakami-Kubo, K. Sasaki, S. Mohri, R. Race, and T. Iwaki. 2004. Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J. Virol. 78:4999-5006.
10. Doh-Ura, K., T. Kuge, M. Uomoto, K. Nishizawa, Y. Kawasaki, and M. Iha. 2007. Prophylactic effect of dietary seaweed fucoidan against enteral prion infection. Antimicrob. Agents Chemother. 51:2274-2277.
11. Fischer, M., T. Rulieke, A. Raeber, A. Sailer, M. Moser, B. Oesch, S. Brandner, A. Aguzzi, and C. Weissmann. 1996. Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO J. 15:1255-1264.
12. Forloni, G., S. Iussich, T. Awan, L. Colombo, N. Angeretti, L. Girola, I. Bertani, G. Poli, M. Caramelli, M. Grazia Bruzzone, L. Farina, L. Limido, G. Rossi, G. Giaccone, J. W. Ironside, O. Bugiani, M. Salmona, and F. Tagliavini. 2002. Tetracyclines affect prion infectivity. Proc. Natl. Acad. Sci. USA 99:10849-10854.
13. Gilch, S., C. Kehler, and H. M. Schatzl. 2006. The prion protein requires cholesterol for cell surface localization. Mol. Cell Neurosci. 31:346-353.
14. Ishikawa, K., K. Doh-ura, Y. Kudo, N. Nishida, I. Murakami-Kubo, Y. Ando, T. Sawada, and T. Iwaki. 2004. Amyloid imaging probes are useful for detection of prion plaques and treatment of transmissible spongiform encephalopathies. J. Gen. Virol. 85:1785-1790.
15. Ishikawa, K., Y. Kudo, N. Nishida, T. Suemoto, T. Sawada, T. Iwaki, and K. Doh-ura. 2006. Styrylbenzoazole derivatives for imaging of prion plaques and treatment of transmissible spongiform encephalopathies. J. Neurochem. 99:198-205.
16. Kempster, S., C. Bate, and A. Williams. 2007. Simvastatin treatment prolongs the survival of scrapie-infected mice. Neuroreport 18:479-482.
17. Mok, S. W., K. M. Thelen, C. Riemer, T. Bamme, S. Gultner, D. Lutjohann, and M. Baier. 2006. Simvastatin prolongs survival times in prion infections of the central nervous system. Biochem. Biophys. Res. Commun. 348:697-702.
18. Murakami-Kubo, I., K. Doh-Ura, K. Ishikawa, S. Kawatake, K. Sasaki, J. Kira, S. Ohta, and T. Iwaki. 2004. Quinoline derivatives are therapeutic candidates for transmissible spongiform encephalopathies. J. Virol. 78:1281-1288.
19. Okamura, N., T. Suemoto, H. Shimadzu, M. Suzuki, T. Shiomitsu, H. Akatsu, T. Yamamoto, M. Staufenbiel, K. Yanai, H. Arai, H. Sasaki, Y. Kudo, and T. Sawada. 2004. Styrylbenzoxazole derivatives for in vivo imaging of amyloid plaques in the brain. J. Neurosci. 24:2535-2541.
20. Okamura, N., T. Suemoto, S. Furumoto, M. Suzuki, H. Shimadzu, H. Akatsu, T. Yamamoto, H. Fujiwara, M. Nemoto, M. Maruyama, H. Arai, K. Yanai, T. Sawada, and Y. Kudo. 2005. Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. J. Neurosci. 25:10857-10862.
21. Otto, M., L. Cepek, P. Ratzka, S. Doehlinger, I. Boekhoff, J. Wiltfang, E. Irle, G. Pergande, B. Ellers-Lenz, O. Windl, H. A. Kretzschmar, S. Poser, and H. Prange. 2004. Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study. Neurology 62:714-718.
22. Parry, A., I. Baker, R. Stacey, and S. Wimalaratna. 2007. Long term survival in a patient with variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulphate. J. Neurol. Neurosurg. Psychiatry 78:733-734.
23. Prusiner, S. B., M. P. McKinley, K. A. Bowman, D. C. Bolton, P. E. Bendheim, D. F. Groth, and G. G. Glenner. 1983. Scrapie prions aggregate to form amyloid-like birefringent rods. Cell 35:349-358.
24. Prusiner, S. B. 1991. Molecular biology of prion diseases. Science 252:1515-1522.
25. Race, R. E., B. Caughey, K. Graham, D. Ernst, and B. Chesebro. 1988. Analyses of frequency of infection, specific infectivity, and prion protein biosynthesis in scrapie-infected neuroblastoma cell clones. J. Virol. 62:2845-2849.
26. Race, R. E., S. A. Priola, R. A. Bessen, D. Ernst, J. Dockter, G. F. Rall, L. Mucke, B. Chesebro, and M. B. Oldstone. 1995. Neuron-specific expression of a hamster prion protein minigene in transgenic mice induces susceptibility to hamster scrapie agent. Neuron 15:1183-1191.
27. Rainov, N. G., Y. Tsuboi, P. Krolak-Salmon, A. Vighetto, and K. Doh-Ura. 2007. Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate? Expert Opin. Biol. Ther. 7:713-726.
28. Sadowski, M., J. Pankiewicz, H. Scholtzova, J. Tsai, Y. Li, R. I. Carp, H. C. Meeker, P. Gambetti, M. Debnath, C. A. Mathis, L. Shao, W. B. Gan, W. E. Klunk, and T. Wisniewski. 2004. Targeting prion amyloid deposits in vivo. J. Neuropathol. Exp. Neurol. 63:775-784.
29. Schroder, H. C., and W. E. Muller. 2002. Neuroprotective effect of flupirtine in prion disease. Drugs Today 38:49-58.
30. Smid, L. M., T. D. Vovko, M. Popovic, A. Petric, V. Kepe, J. R. Barrio, G. Vidmar, and M. Bresjanac. 2006. The 2,6-disubstituted naphthalene derivative FDDNP labeling reliably predicts Congo red birefringence of protein deposits in brain sections of selected human neurodegenerative diseases. Brain Pathol. 16:124-130.
31. Taraboulos, A., M. Scott, A. Semenov, D. Avrahami, L. Laszlo, and S. B. Prusiner. 1995. Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform. J. Cell Biol. 129:121-132.
32. Trevitt, C. R., and J. Collinge. 2006. A systematic review of prion therapeutics in experimental models. Brain 129:2241-2265.